Prosecution Insights
Last updated: July 17, 2026
Application No. 18/279,933

AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Non-Final OA §102§112
Filed
Sep 01, 2023
Priority
Mar 04, 2021 — CN 202110264844.7 +1 more
Examiner
SHTERENGARTS, SAMANTHA L
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Fukang (Shanghai) Health Technology Co. Ltd.
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1337 granted / 1685 resolved
+19.3% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
67 currently pending
Career history
1722
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.5%
-21.5% vs TC avg
§102
24.0%
-16.0% vs TC avg
§112
22.3%
-17.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1685 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority 2. The instant application claims is a national stage entry of PCT/CN2022/079388, filed March 4, 2022. 3. Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d) by application no. CN202110264844.7 filed in the Chinese Patent Office March 4, 2021, which papers have been placed of record in the file. The application names an inventor or inventors named in the prior application. Information Disclosure Statement 4. The information disclosure statements (IDS) submitted on September 1, 2023 is in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS document was considered. A signed copy of form 1449 is enclosed herewith. Election/Restrictions 5. Applicant’s election with traverse of Group I in the reply filed on March 23, 2026 is acknowledged. The traversal is on the ground(s) that all claims are so linked to form a single general inventive concept as they all depend on claim 1. This is not found persuasive because there is not a general inventive concept. For example, in Group I, claim 1 contains the compounds of formula I but claim 7 contains the compounds of formula II-a which are structurally divergent. Additionally, even if there was a general inventive concept across all groups, such as compounds of formula I, they do not make a contribution over the prior art as evidenced by the art rejections herein. Therefore, the claims lack unity of invention and the lack of unity requirement is maintained. The requirement is still deemed proper and is therefore made FINAL. 6. In accordance with the MPEP 803.02, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species, the search of the Markush-type claim will be extended (see MPEP 803.02). If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be reexamined. Id. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. Id. In the event prior art is found during reexamination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. Id. 7. As per MPEP 803.02, the Examiner will determine whether the entire scope of the claims is patentable. Applicants' elected species PNG media_image1.png 204 230 media_image1.png Greyscale makes a contribution over the prior art of record. Therefore, according to MPEP 803.02: should the elected species appear allowable, the search of the Markush-type claim will be extended. If art is found on a non-elected species, the Markush-type claim shall be rejected and claims to the nonelected invention held withdrawn from further consideration. Since art was found on a non-elected species, subject matter not embraced by the elected species is therefore withdrawn from further consideration. It has been determined that the entire scope claimed is not patentable. Status of Claims 8. Claims 1-19 are pending in the instant application. The elected species PNG media_image1.png 204 230 media_image1.png Greyscale reads on the present claims wherein X and Y are Cl, A is O, M is PNG media_image2.png 108 76 media_image2.png Greyscale , R1 is PNG media_image3.png 68 60 media_image3.png Greyscale . Applicant notes that claims 1, 3, 7-8, and 11 read on an elected species; however, claims 2, 4-5, 12, and 18-19 also read on the elected species and claim 7 does not read on the elected species. Therefore, claims 6-7, 9-10, and 13-17 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a non-elected invention and species. Therefore, claims 1-5, 8, 11-12, and 18-19 read on an elected invention and species and are therefore under consideration in the instant application. Claim Rejections - 35 USC § 112 9. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 10. Claims 2, 3, 5, 11, 12, and 19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 recites the following limitations: PNG media_image4.png 78 530 media_image4.png Greyscale It is unclear how the ‘or’ portion of ‘and/or’ is functioning in the present claims. The ‘or’ renders the claim indefinite and Examiner cannot ascertain the metes and bounds of the claimed scope. Claim 3 recites “when R1 is C2 to C6 alkenyl, the C2-C6 alkenyl is” but the ‘when’ renders the claim indefinite as claim 1, from which claim 3 depends, is limited to only C2-C6 alkenyl in the definition of R1. Examiner cannot ascertain the metes and bounds of the claimed scope. Claim 5 recites the following limitations: PNG media_image5.png 212 673 media_image5.png Greyscale . It is unclear how the ‘or’ portion of ‘and/or’ is functioning in the present claims. The ‘or’ renders the claim indefinite and Examiner cannot ascertain the metes and bounds of the claimed scope. Claim 11 recites “when R1 is C2 to C6 alkenyl, the C2-C6 alkenyl is” but the ‘when’ renders the claim indefinite as claim 1, from which claim 11 depends, is limited to only C2-C6 alkenyl in the definition of R1. Examiner cannot ascertain the metes and bounds of the claimed scope. Claim 11 recites the following limitations: PNG media_image6.png 65 473 media_image6.png Greyscale Variable R2 and all moieties containing R2 are cancelled from claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 12 recites the following limitations: PNG media_image5.png 212 673 media_image5.png Greyscale . It is unclear how the ‘or’ portion of ‘and/or’ is functioning in the present claims. The ‘or’ renders the claim indefinite and Examiner cannot ascertain the metes and bounds of the claimed scope. Claim 19 recites the following limitations: PNG media_image7.png 73 577 media_image7.png Greyscale PNG media_image8.png 343 596 media_image8.png Greyscale and another full page of ‘and/or’ limitations. It is unclear how the ‘and’ portion of ‘and/or’ is functioning in the present claims. The ‘and’ renders the claims indefinite as each of these variables cannot have multiple definitions of the same variable. Examiner cannot ascertain the metes and bounds of the claimed scope. Claim 19 recites variable definitions and permutations for variable R2; however, variable R2 does not appear in the formulae of claim 18. There is insufficient antecedent basis for this limitation in the claim. 11. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. 12. Claims 2, 4, and 12 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 2 defines “ PNG media_image9.png 30 260 media_image9.png Greyscale PNG media_image10.png 29 173 media_image10.png Greyscale .” Variables X and Y of claim 2 fail to include all limitations and fail to further limit the claim from which it depends. Claim 4 is drawn to various Schemes 1-3, all of which are outside the scope of claim 1, from which claim 4 depends. All variables of Schemes 1-3, including but not limited to, A, X, Y, M, R1, and R2 are broader defined in claim 4 than they are in claim 1 and therefore fail to include all limitations and fail to further limit the claim from which it depends. Claim 12 defines “ PNG media_image11.png 95 314 media_image11.png Greyscale .” Variable R1 of claim 12 is broaded than that of claim 1, fails to include all limitations and fail to further limit the claim from which it depends. Claim 12 recites as follows: PNG media_image12.png 32 511 media_image12.png Greyscale PNG media_image13.png 486 590 media_image13.png Greyscale . The compounds fall outside the scope of claim 1, fails to include all limitations and fail to further limit the claim from which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 13. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 14. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. 15. Claims 4, 8, and 18-19 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by US 2023/0242492. US 2023/0242492 teaches anticipatory compounds, tautomers, and compositions, including for example: PNG media_image14.png 239 320 media_image14.png Greyscale wherein X and Y are Cl, A is CH2, R1 is isopropyl. Conclusion 16. Claim 1 is allowed. 17. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samantha Shterengarts whose telephone number is (571)270-5316. The examiner can normally be reached on Monday thru Thursday 9-6pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAMANTHA L SHTERENGARTS/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Sep 01, 2023
Application Filed
Jun 17, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12679837
AMINOPYRIMIDINE COMPOUND AS CDK2/4/6 TRIPLE INHIBITOR
4y 3m to grant Granted Jul 14, 2026
Patent 12679852
METHOD FOR PREPARING AN ENANTIOMERICALLY ENRICHED FORM OF 3-(2-CHLOROTHIAZOL-5-YL)-8-METHYL-7-OXO-6-PHENYL-2,3-DIHYDROTHIAZOLO[3,2-A]PYRIMIDIN-4-IUM-5-OLATE
2y 12m to grant Granted Jul 14, 2026
Patent 12673917
NEW BISPHENOLS BEARING PENDANT CLICKABLE NORBORNENYL GROUP AND POLYMERS THEREFROM
3y 0m to grant Granted Jul 07, 2026
Patent 12673050
Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency
2y 6m to grant Granted Jul 07, 2026
Patent 12673939
METHODS OF SYNTHESIS OF HETEROARYL DERIVATIVES OF TRIAZOLYL ACRYLAMIDES AND CRYSTALLINE FORMS
2y 7m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
87%
With Interview (+8.0%)
2y 1m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1685 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month